Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants on Inpatient Clinical Outcome

被引:23
作者
Robinson, Matthew L. [1 ,8 ]
Morris, C. Paul [2 ,3 ]
Betz, Joshua F. [4 ]
Zhang, Yifan [4 ]
Bollinger, Robert [1 ]
Wang, Natalie [5 ]
Thiemann, David R. [6 ]
Fall, Amary [2 ]
Eldesouki, Raghda E. [2 ]
Norton, Julie M. [2 ]
Gaston, David C. [2 ]
Forman, Michael [2 ]
Luo, Chun Huai [2 ]
Zeger, Scott L. [4 ]
Gupta, Amita [1 ]
Garibaldi, Brian T. [7 ]
Mostafa, Heba H. [2 ]
机构
[1] Johns Hopkins Univ, Dept Med, Div Infect Dis, Sch Med, Baltimore, MD USA
[2] Johns Hopkins Univ, Dept Pathol, Sch Med, Baltimore, MD USA
[3] Natl Inst Allergy & Infect Dis, NIH, Bethesda, MD USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA
[5] Johns Hopkins Univ, Krieger Sch Arts & Sci, Baltimore, MD USA
[6] Johns Hopkins Univ, Dept Med, Div Cardiol, Sch Med, Baltimore, MD USA
[7] Johns Hopkins Univ, Dept Med, Div Pulm & Crit Care, Sch Med, Baltimore, MD USA
[8] Johns Hopkins Univ, Sch Med, 725 N Wolfe St, Fisher Ctr Suite 216, Baltimore, MD 21205 USA
基金
美国国家卫生研究院;
关键词
SARS-CoV-2; COVID-19; Delta variant; Omicron variant; inpatient outcomes;
D O I
10.1093/cid/ciac957
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Prior observation has shown differences in COVID-19 hospitalization risk between SARS-CoV-2 variants, but limited information describes hospitalization outcomes. Methods Inpatients with COVID-19 at 5 hospitals in the eastern United States were included if they had hypoxia, tachypnea, tachycardia, or fever, and SARS-CoV-2 variant data, determined from whole-genome sequencing or local surveillance inference. Analyses were stratified by history of SARS-CoV-2 vaccination or infection. The average effect of SARS-CoV-2 variant on 28-day risk of severe disease, defined by advanced respiratory support needs, or death was evaluated using models weighted on propensity scores derived from baseline clinical features. Results Severe disease or death within 28 days occurred for 977 (29%) of 3369 unvaccinated patients and 269 (22%) of 1230 patients with history of vaccination or prior SARS-CoV-2 infection. Among unvaccinated patients, the relative risk of severe disease or death for Delta variant compared with ancestral lineages was 1.30 (95% confidence interval [CI]: 1.11-1.49). Compared with Delta, the risk for Omicron patients was .72 (95% CI: .59-.88) and compared with ancestral lineages was .94 (.78-1.1). Among Omicron and Delta infections, patients with history of vaccination or prior SARS-CoV-2 infection had half the risk of severe disease or death (adjusted hazard ratio: .40; 95% CI: .30-.54), but no significant outcome difference by variant. Conclusions Although risk of severe disease or death for unvaccinated inpatients with Omicron was lower than with Delta, it was similar to ancestral lineages. Severe outcomes were less common in vaccinated inpatients, with no difference between Delta and Omicron infections. Unvaccinated adults hospitalized with COVID-19 with Delta infections had increased risk of requiring advanced respiratory support or dying within 28 days, compared with Omicron and ancestral lineages, which were similar. Vaccination lowered severe disease risk, with no Omicron versus Delta difference.
引用
收藏
页码:1539 / 1549
页数:11
相关论文
共 42 条
[1]  
Aksamentov I., 2021, J. Open Source Softw., V6, P3773, DOI [10.21105/joss.03773, DOI 10.21105/JOSS.03773]
[2]   Experimental Implementation of State-Dependent Riccati Equation Control on Quadrotors [J].
Nekoo, Saeed Rafee ;
Ollero, Anibal .
DRONE SYSTEMS AND APPLICATIONS, 2025,
[3]   Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study [J].
Bager, Peter ;
Wohlfahrt, Jan ;
Fonager, Jannik ;
Rasmussen, Morten ;
Albertsen, Mads ;
Michaelsen, Thomas Yssing ;
Moller, Camilla Holten ;
Ethelberg, Steen ;
Legarth, Rebecca ;
Button, Mia Sarah Fischer ;
Gubbels, Sophie ;
Voldstedlund, Marianne ;
Molbak, Kare ;
Skov, Robert Leo ;
Fomsgaard, Anders ;
Krause, Tyra Grove .
LANCET INFECTIOUS DISEASES, 2021, 21 (11) :1507-1517
[4]   Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant [J].
Bernal, Jamie Lopez ;
Andrews, Nick ;
Gower, Charlotte ;
Gallagher, Eileen ;
Simmons, Ruth ;
Thelwall, Simon ;
Stowe, Julia ;
Tessier, Elise ;
Groves, Natalie ;
Dabrera, Gavin ;
Myers, Richard ;
Campbell, Colin N. J. ;
Amirthalingam, Gayatri ;
Edmunds, Matt ;
Zambon, Maria ;
Brown, Kevin E. ;
Hopkins, Susan ;
Chand, Meera ;
Ramsay, Mary .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07) :585-594
[5]   Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant [J].
Bhattacharyya, Roby P. ;
Hanage, William P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (07)
[6]   Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar [J].
Butt, Adeel A. ;
Dargham, Soha R. ;
Chemaitelly, Hiam ;
Al Khal, Abdullatif ;
Tang, Patrick ;
Hasan, Mohammad R. ;
Coyle, Peter, V ;
Thomas, Anil G. ;
Borham, Abdelsalam M. ;
Concepcion, Elli G. ;
Kaleeckal, Anvar H. ;
Latif, Ali Nizar ;
Bertollini, Roberto ;
Abou-Samra, Abdul-Badi ;
Abu-Raddad, Laith J. .
JAMA INTERNAL MEDICINE, 2022, 182 (02) :197-205
[7]  
Centers for Disease Control and Prevention, COVID DAT TRACK
[8]  
Centers for Disease Control and Prevention, SARS-CoV-2 Variant Classifications and Definitions
[9]  
Chesapeake Regional Information System for our Patients, CLIN DAT
[10]  
Clarke KEN, 2022, MMWR-MORBID MORTAL W, V71, P606, DOI 10.15585/mmwr.mm7117e3